Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss).

Shepherd BS, Johnson JK, Silverstein JT, Parhar IS, Vijayan MM, McGuire A, Weber GM

Comparative biochemistry and physiology. Part A, Molecular & integrative physiology24 Nov 2006Cited by 59 (Europe PMC)

PMID17240179DOI10.1016/j.cbpa.2006.11.004PepBankPUB-17240179

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, feed intake was significantly elevated at 2 and 5 h after injection of KP-102 (GHRP‑2) and the other GH secretagogues tested.
In plain wordsIn rainbow trout, KP-102 injection increased feeding within 5 hours, as did the other tested growth hormone boosters.
Peptide
GHRP-2
Outcome
IncreaseFeed intake at 2 and 5 h
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Feed intake was significantly elevated by all of the GHSs tested at both post-injection time points.
2 context sentences(design, population, supporting numbers)
Summary · context
Feed intake was tested at 2 and 5 h post-injection and plasma levels of growth hormone (GH), IGF-I and the IGFBPs were determined at 3, 6 and 12 h post-injection.
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017901
02AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, KP-102 (GHRP‑2) and the other GH secretagogues tested elevated plasma GH levels in a time-dependent manner.
In plain wordsIn rainbow trout, KP-102 raised blood growth hormone over time, as did the other tested growth hormone boosters.
Peptide
GHRP-2
Outcome
IncreasePlasma GH
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
All GHSs elevated plasma GH levels in a time-dependent manner.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017902
03AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, plasma IGF-I levels were elevated at 3 h after KP-102 injection.
In plain wordsIn rainbow trout, blood IGF-I was higher 3 hours after KP-102 injection.
Peptide
GHRP-2
Outcome
IncreasePlasma IGF-I at 3 h
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Plasma IGF-I levels were elevated by all GHSs at 3 h post-injection, whereas those animals treated with KP-102 and ghrelin exhibited depressions at 6 h.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017903
04AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, plasma IGF-I showed depressions at 6 h after KP-102 injection.
In plain wordsIn rainbow trout, blood IGF-I was lower 6 hours after KP-102 injection.
Peptide
GHRP-2
Outcome
DecreasePlasma IGF-I at 6 h
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Plasma IGF-I levels were elevated by all GHSs at 3 h post-injection, whereas those animals treated with KP-102 and ghrelin exhibited depressions at 6 h.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017904
05AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, levels of the 32 kDa IGFBP were significantly depressed by KP-102 and the other GH secretagogues tested.
In plain wordsIn rainbow trout, KP-102 lowered a blood IGF-binding protein of 32 kDa, as did the other tested growth hormone boosters.
Peptide
GHRP-2
Outcome
DecreasePlasma 32 kDa IGFBP
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Levels of the 32 kDa IGFBP were significantly depressed by all GHSs tested.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017905
06AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout, levels of the 42 kDa IGFBP were significantly elevated by KP-102 and the other GH secretagogues tested.
In plain wordsIn rainbow trout, KP-102 raised a blood IGF-binding protein of 42 kDa, as did the other tested growth hormone boosters.
Peptide
GHRP-2
Outcome
IncreasePlasma 42 kDa IGFBP
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Levels of the 42 kDa IGFBP were significantly elevated by all GHSs tested.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017906
07AnimalAnimal study (in vivo)Efficacy outcome
In rainbow trout injected with GH secretagogues (GHRH, KP-102 or ghrelin), plasma 50 kDa IGFBP decreased in some treatment groups at 3 h and was elevated in all treatment groups by 12 h post-injection; the abstract does not say which groups.
In plain wordsIn trout given growth hormone boosters, a 50 kDa blood protein fell in some groups at 3 hours and rose in all by 12 hours.
Peptide
GHRP-2
Outcome
MixedPlasma 50 kDa IGFBP over time
Study
rainbow trout (Oncorhynchus mykiss)n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 or 10 pmol/g body massAs given in this study (rainbow trout (Oncorhynchus mykiss)).
Source sentences
Summary
Plasma levels of the 50 kDa IGFBP was decreased in some treatment groups at 3 h, but elevated by 6 h in the ghrelin-treated groups and elevated in all treatment groups by 12 h post-injection.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass.
Report a problemFND-1724017907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.